Cargando…

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α

OBJECTIVE: Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stromal-derived factor-1α (SDF-1α) and are reduced in type 2 diabetes. Because SDF-1α is a substrate of dipeptidyl-peptidase-4 (DPP-4), we investigated whether the DPP-4 inhibitor sitagliptin modulates EPC levels in ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Boscaro, Elisa, Albiero, Mattia, Menegazzo, Lisa, Frison, Vera, de Kreutzenberg, Saula, Agostini, Carlo, Tiengo, Antonio, Avogaro, Angelo
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890368/ https://www.ncbi.nlm.nih.gov/pubmed/20357375 http://dx.doi.org/10.2337/dc10-0187

Ejemplares similares

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Impaired Hematopoietic Stem/Progenitor Cell Traffic and Multi-organ Damage in Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms
por: de Kreutzenberg, Saula Vigili, et al.
Publicado: (2010)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
por: Kubota, Yoshiaki, et al.
Publicado: (2012)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease
por: Vigili de Kreutzenberg, Saula, et al.
Publicado: (2022)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor
por: Maita, Hiroki, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
por: Komatsu, Tomohiro, et al.
Publicado: (2023)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
por: Wilson, Jessica R, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
por: Li, Jingjing, et al.
Publicado: (2014)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
por: Zheng, Wenbin, et al.
Publicado: (2018)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kgp8pde10jl4q7sru8qh38c7ll